Within the past few years, clinical outcomes of MM have improved due to the introduction of several new agents such as the third-generation immunomodulators (IMiD), next-generation proteasome inhibitors (PIs), anti-CD38 monoclonal antibodies (mAbs), B-cell maturation antigen (BCMA) antibody drug conjugates (ADCs), and BCMA-directed chimeric antigen receptor (CAR) T-cell therapy16
- However, 5-year survival in the US remains at 55.6%.22
Despite multiple novel therapeutic options, the optimal combination as well as sequencing of therapy for individual patients remains an important challenge which needs to be addressed. Continued introduction of new agents with non-overlapping mechanisms of action will not only allow for novel multi-agent combinations, but may contribute to continued improvements in outcomes.18,21
AbbVie is committed to helping address these challenges and is actively conducting research in this area to help address this unmet need.